I. The problem — why snakebite treatment hasn't changed
Antivenom has saved millions of lives for over a century — but it needs IV administration in a hospital, a refrigerated cold chain, and is species-specific. It's expensive, can cause serum sickness, and doesn't prevent local tissue damage — people still lose fingers and hands even with it. And it's unavailable in most rural areas where the bites actually happen.
In February 2026, the WHO published Target Product Profiles for two treatment classes: hospital therapeutics, and pre-hospital field treatments that "buy time." The second category — field-deployable, shelf-stable, broad-spectrum, self-administrable — is the gap this proposal aims at.
II. The three components
Three drugs, three venom pathways, one case the size of an EpiPen.
Botulinum Toxin Type A (Botox)
This is the spark. In March 2026, Australian researchers injected Botox into rabbit paws before cobra-venom exposure: swelling dropped ~30%, muscle death fell, and — crucially — Botox shifted macrophages from inflammatory (M1) to tissue-repair (M2) mode. It didn't just reduce damage; it promoted healing. Delivered as a lyophilized (freeze-dried) powder in a dual-chamber autoinjector — shelf-stable for 2–3 years at room temperature, reconstituted with saline at the moment of use.
Unithiol (DMPS)
An already-FDA-approved heavy-metal-poisoning drug. SVMPs are zinc-dependent enzymes; Unithiol grabs the zinc and shuts them off. Phase I trials in Kenya (2025–26) showed it's safe at high doses, rapidly absorbed orally, and reaches therapeutic blood levels in 30–60 minutes. Two 300 mg chewable tablets, 3–5 year shelf life, no refrigeration.
Varespladib
A PLA2 inhibitor that has completed Phase II trials for snakebite. Orally bioavailable, broad-spectrum across snake-venom PLA2 enzymes — and PLA2 is one of the most common toxic components across species, from elapids (cobras, kraits, coral snakes, mambas) to many vipers. One 500 mg capsule, 2–3 year shelf life, no refrigeration.
III. The delivery system & the cost case
The Botox rides in a dual-chamber autoinjector (Windgap-style): dry powder in Chamber 1, saline in Chamber 2. Twist the cap to mix, wait 5–10 seconds for reconstitution, press against the bite, spring-loaded needle deploys. One-handed — critical for solo administration. The full kit fits an EpiPen-sized case, weighs under 200 g, stores at room temperature for 2–3 years.
The protocol
- Twist & inject. Mix the Botox, press the injector against the bite, hold 3 seconds.
- Chew Unithiol. Two tablets, immediately.
- Swallow Varespladib. One capsule.
- Bandage & immobilize. Pressure wrap, still the limb.
- Get to a hospital for antivenom if needed. The kit buys time — it may not replace antivenom in severe envenomations.
IV. The coverage — three pathways, one kit
| Venom pathway | Component | Mechanism | Snakes covered |
|---|---|---|---|
| Cytotoxic / myotoxic local tissue & muscle death | Botox | Blocks acetylcholine; shifts macrophages M1→M2 | Cobras, spitting cobras, some rattlesnakes, water moccasins |
| Hemotoxic blood-vessel destruction, bleeding | Unithiol | Chelates zinc in SVMPs, deactivating them | Rattlesnakes, copperheads, pit vipers, Russell's viper, puff adder, Gaboon viper |
| Neurotoxic paralysis, respiratory failure | Varespladib | Blocks PLA2 enzymes | Cobras, kraits, coral snakes, mambas, tiger snakes, taipans |
One universal kit beats five regional variants. Venom chemistry crosses borders — a Tennessee rattlesnake and an Indian Russell's viper both run hemotoxic SVMPs; an Alabama coral snake and a Bangladeshi krait both run neurotoxic PLA2. The delivery animal differs; the chemistry is the same. And you don't have to identify the snake before treating — the kit covers the major pathways regardless.
V. The gaps — what doesn't exist yet
This is the honest asterisk, and it's the part that matters most:
Interaction effects. Nobody has tested Botox + Unithiol + Varespladib together. Different pathways suggest synergy is plausible — but antagonism is also possible. That's the first thing lab testing needs to settle.
Dosing precision. Human bites vary wildly, from dry bites to full envenomations. The kit may need strength variants, or a single max-dose approach on the logic that over-treating a mild bite beats under-treating a severe one.
Species outliers. Sea snakes and some Australian elapids carry venom components outside these three pathways — partial, not complete, coverage.
Regulatory pathway. Botox-for-snakebite is brand new (March 2026); Unithiol and Varespladib are in trials but not approved for this indication. Repurposing approved drugs is faster than new-drug development, but still needs Phase I–III. Realistic timeline: prototype in 2–3 years, commercial product in 5–7 if funding and approval align.
VI. How this happened
This wasn't designed by a pharmacologist or a biotech startup. It was designed by a guy reading weird news who saw the Botox-and-snakebite headline and went "oh shit, hell yeah, let me dive off in this direction." Four prompts — about 45 minutes — took it from "huh, that's interesting" to a three-component kit with dosing, delivery design, cost estimates, and a global coverage analysis.
That doesn't make the proposal ready for clinical use. It means the starting point for research — the framework, the component selection, the standardization argument — can emerge from curiosity plus AI collaboration in under an hour. The traditional path produces rigor over years. The Page 14-B path produces the idea the rigor gets applied to. Both have value; they just sit at different ends of the same pipeline.
Companion: the Page 14-B method, made interactive — Browse → Philosophy → Attack, the mechanism behind this kit.
"Probability of this kit saving lives if funded and tested: 73.2%. Probability of a researcher reading this and recognizing the combination is novel: 94.7%. Probability of funding arriving before the next 80,000 people die from snakebites: insufficient data. Eat your fish sticks. They exist in all probability states."